BSACI response to the article (Nurek M, Rayner C, Fryer A et al. Recommendations for the recognition, diagnosis and management of long COVID. Br J Gen Pract 2021; 71:e815-e825) published online by BJGP - BSACI

BSACI response to the article (Nurek M, Rayner C, Fryer A et al. Recommendations for the recognition, diagnosis and management of long COVID. Br J Gen Pract 2021; 71:e815-e825) published online by BJGP

BSACI would like to respond to the article by Nurek1 et al. We appreciate this is a growing area of interest, and that further research is needed, but we feel that this article makes conclusions that are not supported by evidence, and which has the potential to trigger unnecessary referrals to allergy and immunology clinics which are already facing huge pressures.

In Box 1, described as ‘Known examples of conditions associated with long COVID’, included are ‘Mast cell activation, including urticaria, angioedema and histamine intolerance’, along with ‘new-onset allergies and anaphylaxis’. It has been recognised that SARS-CoV-2 infection can be associated with urticaria and angioedema,2 as is the case with many infections,3 but there is no evidence to suggest that acute infection or long COVID causes new allergic sensitisation or manifestations of allergic or atopic diseases including anaphylaxis. Similarly, it is not clear that urticaria itself is increased in long COVID, after the initial phase of infection. The term ‘histamine intolerance’ can be misleading in that there is no clear evidence to support a role for ingested histamine in chronic urticaria, a well recognised auto-immune disorder. 4,5

The authors draw parallels between the symptoms of ‘mast cell activation syndrome (MCAS)’ and those of long COVID, and suggest this this diagnosis should be considered in patients with a broad range of symptoms. They acknowledge as do we that MCAS is a controversial area with no clear diagnostic criteria. An association between autonomic dysfunction and mast cell disorders is suggested, although in fact this remains unproven and based predominantly on symptom reporting.6 They then offer recommendations for treatment including low histamine diets, antihistamines and montelukast, and suggest referral to immunology or allergy specialists. No evidence is provided to support the use of low histamine diets, or an association between MCAS and long COVID. This is an interesting area for further research, but the evidence is not there for this to be put forward as a recommendation to family doctors.

We understand that the article represents the lived experience of a number of doctors dealing with long COVID, and is an attempt to shed light on possible mechanisms and treatment approaches. However, the casual reader may assume the recommendations carry the same weight as for instance a NICE guideline.

We are concerned that no specialists the field of allergy or immunology were involved in the publication. We do  not feel that referral of patients with non-specific symptoms to allergy/immunology clinics is appropriate, unless there is a clear clinical question requiring assessment of a possible specific allergic trigger.

NICE has published detailed guidance for investigation and management of long COVID.7 SIGN guidelines also include specific advice on management of urticaria and angioedema in the context of long COVID, which emphasises that no different management strategies are required.8 Considerable investment has been made by NHS England into long COVID services which are now starting to develop across the UK.9 We would encourage family doctors to use the published NICE and SIGN guidance when assessing patients and to use approved referral pathways.

1. Nurek M, Rayner C, Fryer A et al. Recoomendations for the recognition, diagnosis and management of long COVID. Br J Gen Pract 2021; 71:e815-e825.

2. Abuelgasim, E, Dona, ACM, Sondh, RS, Harky, A. Management of urticaria in COVID-19 patients: A systematic review. Dermatologic Therapy. 2021; 34:e14328.

3. Wedi B, Raap U, Wieczorek D, Kapp A. Urticaria and infections. Allergy Asthma Clin Immunol. 2009;5(1):10. Published 2009 Dec 1.

4. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update. Allergy 2018; 73: 1393–1414.

5. Powell RJ, Leech SC, Till S, Huber PA, Nasser SM, Clark AT; British Society for Allergy and Clinical Immunology. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015 Mar;45(3):547-65.

6. Kohn A and Chang C. The Relationship Between Hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), and Mast Cell Activation Syndrome (MCAS). Clin Rev Allergy Immunol 2020 Jun;58(3):273-297

7. Guideline COVID-19 rapid guideline: managing the long-term effects of COVID-19 (

8.  Annex C